Introduction : Drug–drug interactions (DDIs) influence treatment outcomes, particularly in complex diseases such as coronavirus disease 2019 (COVID-19). This study aimed to evaluate the impact of DDIs in COVID-19 patients. Materials and methods : A study was conducted on 200 patients with mild, moderate, or severe COVID-19 infections. Next, DDIs were classified into five risk categories (A–X). Results : Altogether, 1689 DDIs were identified (maximum of 64 per patient). Most interactions were category C (65.3%). Clinically significant DDIs (C–X) accounted for 73.6% of interactions. Positive correlations were found between the total number of DDIs and both the total number of drugs (very strong) and comorbidities/diagnoses (strong). Patients with severe COVID-19 infections had significantly more DDIs and drugs used. Polypharmacy was highly frequent (97.5%, average of 9.9 drugs per patient). Conclusion : Overall, COVID-19 patients often have clinically significant DDIs resulting from polypharmacy and comorbidities, especially in severe cases. Systematic DDI assessment is essential.
Introduction : Older adults with type 2 diabetes mellitus (T2DM) frequently present with multiple comorbidities and complex therapeutic regimens, increasing the risk of potentially inappropriate medication (PIM) prescribing. This study aimed to assess the prevalence of PIM prescribing in geriatric patients with T2DM using the 2019 American Geriatrics Society Beers Criteria. Materials and methods : This observational, retrospective study included 400 geriatric patients (≥65 years) with T2DM. Data on prescribed medications were collected from medical records. Statistical analysis was performed using SPSS 13.0 and Microsoft Excel 2019 ( α = 0.05). Results : At least one PIM was identified in 60.8% of patients. Frequently prescribed PIMs included proton pump inhibitors (13.5%), diazepam (10.3%), and digoxin (6.5%) among medications to be avoided, and diuretics (59.5%) and acetylsalicylic acid (19.0%) among medications to be used with caution. Conclusion : Systematic application of the Beers Criteria may improve pharmacotherapy safety in this vulnerable population.